Navigation Links
Researchers discover possible approach to the treatment of aggressive breast cancer
Date:3/6/2012

This release is available in German.

In particularly aggressive forms of breast cancer, cancer cells can settle in other organs and form metastases there. Once such metastases form, complete recovery is rare. Consequently, it is enormously important to prevent the metastasisation of the breast cancer cells. The success, however, achieved by using existing forms of therapy is limited. Scientists from the Max Planck Institute for Heart and Lung Research in Bad Nauheim have now discovered that they can prevent the formation of metastases by blocking the receptor protein Plexin B1. They hope that their discovery will provide a new approach to preventing the metastasisation of aggressive forms of breast cancer, and thus improve the prognosis for patients.

Breast cancer is by far the most common form of cancer in women. Around one in ten women will suffer from the disease at some point in their lives. Around one quarter of all patients suffer from a particularly aggressive form of breast cancer, in which the tumour cells frequently metastasise in other organs. This aggressive form of breast cancer is characterised by the fact that the tumour cells produce the protein ErbB-2. If ErbB-2 is detected in the tumour cells in the tissue sample taken routinely from all breast cancer patients, they must undergo special and complicated therapy. Despite this treatment, it is not always possible to prevent the emergence of metastases.

Scientists from the research group of Stefan Offermanns, Director of the Max Planck Institute for Heart and Lung Research, have now discovered precisely what it is that makes ErbB-2-producing tumours so aggressive. "It was already known from tests on the nervous system that ErbB-2 forms a complex with the receptor protein Plexin-B1 which controls the movement and migration of cells," explains Thomas Worzfeld, leader of the research study. "For this reason we specifically looked for interaction between these two proteins in breast cancer cells." The Bad Nauheim researchers struck gold. When they switched off Plexin-B1 in breast cancer cells, the cells became incapable of migrating.

"We concluded from this observation that it should be possible to prevent the formation of metastases by switching off Plexin-B1," said Worzfeld. To verify this, they switched off the Plexin-B1 in mice with ErbB-2-producing breast cancer. The effect they observed was very clear: "We were able to establish a drastic reduction in the lung metastases in the animals without Plexin-B1. The effect could even be observed with the naked eye."

The next question to be resolved by the scientists concerned the extent to which this observation could be applied to humans. In a test on tissue from breast cancer patients, the Max Planck scientists noted a link between the Plexin-B1 content of the tumour tissue and the patients' prognoses: patients with very low Plexin-B1 content in their tumour tissue had a considerably better chance of survival.

The scientists are hopeful that these findings will provide a basis for the development of a new treatment. "We want to switch Plexin-B1 off specifically using an antibody and in this way suppress the emergence of metastases," said Worzfeld. The antibody, for which a patent has been filed, is now being tested in the animal model. Offermanns is cautiously optimistic: "With Plexin-B1 we believe we have found a crucial location where the formation of metastases can be blocked. However, we still have a very long way to go until our antibody can be successfully used in clinical practice."


'/>"/>

Contact: Dr. Matthias Heil
matthias.heil@mpi-bn.mpg.de
49-603-270-51705
Max-Planck-Gesellschaft
Source:Eurekalert

Related medicine news :

1. Researchers ID gene behind primary cervical dystonia, a neck-twisting disorder
2. Researchers find sarcoma tumor immune response with combination therapy
3. Mayo researchers provide atomic view of a histone chaperone
4. Researchers find potential solution to melanomas resistance to vemurafenib
5. Kessler Foundation researchers present at DC Conference on Race, Ethnicity and Disabilities
6. Researchers Spot Genes Behind Macular Degeneration
7. 90 percent of firefighters exhibit symptoms of PTSD according to Ben-Gurion University researchers
8. New blood test for early cancer detection developed by Ben-Gurion University researchers
9. UC Davis MIND Institute researchers to present on autism at AAAS Annual Meeting in Vancouver
10. Nasty superbug is being studied by UB researchers
11. Researchers see differences in Autism brain development as early as 6 months
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... ... Cosmetic Town, an online plastic surgery community, begins 2017 with an update ... their readers to get the information they desire. The procedures are now listed according ... on those particular areas. , “We are excited to streamline our listings in a ...
(Date:1/19/2017)... Plains, NJ (PRWEB) , ... January 19, 2017 ... ... board certified dermatologist by the American Board of Dermatology and fellowship trained Mohs ... of the National Institutes of Health, Dr. Li completed his internship in internal ...
(Date:1/19/2017)... Angeles, California (PRWEB) , ... January 19, 2017 ... ... the hands of a doctor who administered fillers that resulted in severe facial ... unprecedented case was taken on by doctors at UCLA Medical Center, who removed ...
(Date:1/19/2017)... ... January 19, 2017 , ... Workrite Ergonomics ... , The Tranquility privacy panel system was designed to deliver the ideal ... help reduce noise and provide the visual privacy required to maintain concentration levels ...
(Date:1/19/2017)... Francisco, CA (PRWEB) , ... January 19, 2017 , ... ... financial planning assistance to commercial and residential clients in the California Bay Area, is ... positive heart health in the region. , Heart disease is the primary killer of ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)...   Science Exchange , the leading marketplace ... the first five replication studies from the ... in eLife today. Despite intense scrutiny around reproducibility ... evaluation of reproducibility rates that may identify specific ... assessments of reproducibility, the results of this project ...
(Date:1/19/2017)... January 18, 2017 , , Marks E-QURE ... distribution agreement, following similar agreements in Israel ... Wound care is $2 5 billion ... E-QURE Corp. (OTCQB: EQUR), a leader in medical devices for the treatment of ... Médica Equipos Médicos S.A.S. (TeckMedica) in Colombia for the ...
(Date:1/19/2017)... , Jan. 18, 2017 The drug ... billion by 2021 from USD 1,179.20 billion in 2016, ... Increasing prevalence of chronic diseases, increasing demand for ... factors driving the growth of this market. Whereas, self-administration ... generic drugs offer significant growth opportunities for players operating ...
Breaking Medicine Technology: